Elena Sotiriou

Dr. Elena Sotiriou

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2009 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ZAZ. Apalla
Z. Apalla
ESElena Sotiriou
Elena Sotiriou
ECE. Chovarda
E. Chovarda
ILI. Lefaki
I. Lefaki
DDD. Devliotou-Panagiotidou
D. Devliotou-Panagiotidou
DID. Ioannides
D. Ioannides

1 September 2009 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ESElena Sotiriou
Elena Sotiriou
ZAZ Apalla
Z Apalla
FMF Maliamani
F Maliamani
NZN Zaparas
N Zaparas
DPD Panagiotidou
D Panagiotidou
DID Ioannides
D Ioannides

7 August 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ESElena Sotiriou
Elena Sotiriou
ATAikaterini Tsentemeidou
Aikaterini Tsentemeidou
KBK. Bakirtzi
K. Bakirtzi
Aimilios LallasAimilios Lallas
Aimilios Lallas
DIDΙmΙtrios Ioannides
DΙmΙtrios Ioannides
EVE. Vakirlis
E. Vakirlis
Click on the article title to read more.

24 October 2017 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ESElena Sotiriou
Elena Sotiriou
GEG Evangelou
G Evangelou
EPE Papadavid
E Papadavid
ZAZ Apalla
Z Apalla
FVF Vrani
F Vrani
DID Ioannides
D Ioannides

24 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSNikolaos Sideris
Nikolaos Sideris
EPEleni Paschou
Eleni Paschou
KBKaterina Bakirtzi
Katerina Bakirtzi
DKDimitra Kiritsi
Dimitra Kiritsi
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
EVEfstratios Vakirlis
Efstratios Vakirlis
Atopic dermatitis (AD) is a chronic inflammatory dermatosis with periods of exacerbation and remissions. AD is characterized by intense, persistent pruritus and heterogeneity in clinical symptomatology and severity. Therapeutic goals include the amelioration of cutaneous eruptions, diminishing relapses and eventually the disease burden. To date, topical corticosteroids (TCS) and calcineurin inhibitors (TCI) have yet been deemed the mainstay of topical treatments in AD management. Nevertheless, despite their indisputable efficiency, TCS and TCI are not indicated for continuous long-term use given their safety profile. While research in AD has concentrated predominantly on systemic therapies, more than 30 novel topical compounds are under development. The existing data appear encouraging, with some regimens that are already FDA-approved (ruxolitinib was the most recent in September 2021) and several pharmaceutical pipeline products for mild-to-moderate AD that are in an advanced stage of development, such as tapinarof, difamilast and roflumilast. Larger, long-term studies are still required to evaluate the efficacy and safety of these novel compounds in the long run and weigh their advantages over present treatments. In this review, we aim to provide an overview of the latest knowledge about AD topical treatments, echoing upcoming research trends.

2 July 2010 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ESElena Sotiriou
Elena Sotiriou
ZAZ Apalla
Z Apalla
ECE Chovarda
E Chovarda
DPD Panagiotidou
D Panagiotidou
DID Ioannides
D Ioannides